{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:31:43Z","timestamp":1774611103670,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Key Research and Development Program of China","award":["2016YFC1300100"],"award-info":[{"award-number":["2016YFC1300100"]}]},{"name":"the National Key Research and Development Program of China","award":["2016YFC1300100"],"award-info":[{"award-number":["2016YFC1300100"]}]},{"name":"the National Key Research and Development Program of China","award":["2016YFC1300100"],"award-info":[{"award-number":["2016YFC1300100"]}]},{"name":"the National Key Research and Development Program of China","award":["2016YFC1300100"],"award-info":[{"award-number":["2016YFC1300100"]}]},{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["Z171100001117026"],"award-info":[{"award-number":["Z171100001117026"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>Apparent mineralocorticoid excess (AME) is an ultrarare autosomal recessive disorder resulting from deficiency of 11\u03b2-hydroxysteroid dehydrogenase type 2 (11\u03b2HSD2) caused by mutations in <jats:italic>HSD11B2<\/jats:italic>. The purpose of this study was to identify novel compound heterozygous <jats:italic>HSD11B2<\/jats:italic> mutations in a Chinese pedigree with AME and conduct a systematic review evaluating the AME clinical features associated with <jats:italic>HSD11B2<\/jats:italic> mutations.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Next-generation sequencing was performed in the proband, and Sanger sequencing was used to identify candidate variants in family members, 100 hypertensives, and 100 healthy controls. A predicted structure of 11\u03b2HSD2 was constructed by in silico modeling. A systematic review was used to identify cases of <jats:italic>HSD11B2<\/jats:italic>-related AME. Data for genotyping and clinical characterizations and complications were extracted.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Next-generation sequencing showed novel compound heterozygous mutations (c.343_348del and c.1099_1101del) in the proband with early-onset hypertension and hypokalemia. Sanger sequencing verified the monoallelic form of the same mutations in five other relatives but not in 100 hypertensives or 100 healthy subjects. In silico structural modeling showed that compound mutations may simultaneously perturb the substrate and coenzyme binding pocket. A systematic review of 101 AME patients with 54 <jats:italic>HSD11B2<\/jats:italic> mutations revealed early-onset hypertension, hypokalemia and homozygous mutations as common features. The homozygous <jats:italic>HSD11B2<\/jats:italic> mutations correlated with low birth weight (<jats:italic>r<\/jats:italic>\u2009=\u20090.285, <jats:italic>P<\/jats:italic>\u2009=\u20090.02).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>We report novel compound heterozygous <jats:italic>HSD11B2<\/jats:italic> mutations in a Chinese teenager with early-onset hypertension, and enriched genotypic and phenotypic spectrums in AME. Genetic testing helps early diagnosis and treatment for AME patients, which may avoid target organ damage.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s12020-020-02460-9","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T10:09:55Z","timestamp":1597918195000},"page":"607-615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Apparent mineralocorticoid excess caused by novel compound heterozygous mutations in HSD11B2 and characterized by early-onset hypertension and hypokalemia"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6261-9608","authenticated-orcid":false,"given":"Peng","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun-Qi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Liang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"issue":"5","key":"2460_CR1","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1210\/jcem-44-5-924","volume":"44","author":"MI New","year":"1977","unstructured":"M.I. New, L.S. Levine, E.G. Biglieri, J. Pareira, S. Ulick, Evidence for an unidentified steroid in a c hild with apparent mineralocorticoid hypertension. J. Clin. Endocrinol. Metab. 44(5), 924\u2013933 (1977). https:\/\/doi.org\/10.1210\/jcem-44-5-924","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"2460_CR2","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1210\/jcem.80.7.7608290","volume":"80","author":"RC Wilson","year":"1995","unstructured":"R.C. Wilson, Z.S. Krozowski, K. Li, V.R. Obeyesekere, M. Razzaghy-Azar, M.D. Harbison, J.Q. Wei, C.H. Shackleton, J.W. Funder, M.I. New, A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 80(7), 2263\u20132266 (1995). https:\/\/doi.org\/10.1210\/jcem.80.7.7608290","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"2460_CR3","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1210\/jcem.83.7.4986","volume":"83","author":"S Dave-Sharma","year":"1998","unstructured":"S. Dave-Sharma, R.C. Wilson, M.D. Harbison, R. Newfield, M.R. Azar, Z.S. Krozowski, J.W. Funder, C.H. S. hackleton, H.L. Bradlow, J.Q. Wei, J. Hertecant, A. Moran, R.E. Neiberger, J.W. Balfe, A. Fattah, D. Daneman, H.I. Akkurt, C. De Santis, M.I. New, Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess.J. Clin. Endocrinol. Metab. 83(7), 2244\u20132254 (1998). https:\/\/doi.org\/10.1210\/jcem.83.7.4986","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8994","key":"2460_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S0140-6736(96)90211-1","volume":"347","author":"PM Stewart","year":"1996","unstructured":"P.M. Stewart, Z.S. Krozowski, A. Gupta, D.V. Milford, A.J. Howie, M.C. Sheppard, C.B. Whorwood, Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene. Lancet 347(8994), 88\u201391 (1996).","journal-title":"Lancet"},{"issue":"1\u20132","key":"2460_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.mce.2003.10.019","volume":"217","author":"M Quinkler","year":"2004","unstructured":"M. Quinkler, B. Bappal, N. Draper, A.J. Atterbury, G.G. Lavery, E.A. Walker, V. DeSilva, N.F. Taylor, S. Hala, N. Rajendra, P.M. Stewart, Molecular basis for the apparent mineralocorticoid excess syndrome in the Oman population. Mol. Cell Endocrinol. 217(1\u20132), 143\u2013149 (2004). https:\/\/doi.org\/10.1016\/j.mce.2003.10.019","journal-title":"Mol. Cell Endocrinol."},{"issue":"Pt A","key":"2460_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jsbmb.2016.03.010","volume":"165","author":"JW Funder","year":"2017","unstructured":"J.W. Funder, Apparent mineralocorticoid excess. J. Steroid Biochem. Mol. Biol. 165(Pt A), 151\u2013153 (2017). https:\/\/doi.org\/10.1016\/j.jsbmb.2016.03.010","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"3","key":"2460_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/00004872-200018030-00001","volume":"18","author":"P Ferrari","year":"2000","unstructured":"P. Ferrari, E. Lovati, F.J. Frey, The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. J. Hypertens 18(3), 241\u2013248 (2000).","journal-title":"J. Hypertens"},{"key":"2460_CR8","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.12688\/f1000research.8779.2","volume":"5","author":"R Narayanan","year":"2016","unstructured":"R. Narayanan, S. Karuthedath Vellarikkal, R. Jayarajan, A. Verma, V. Dixit, V. Scaria, S. Sivasubbu, Case report: application of whole exome sequencing for accurate diagnosis of rare syndromes of mineralocorticoid excess. F1000Research 5, 1592 (2016). https:\/\/doi.org\/10.12688\/f1000research.8779.2","journal-title":"F1000Research"},{"issue":"4878","key":"2460_CR9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1126\/science.2845584","volume":"242","author":"JW Funder","year":"1988","unstructured":"J.W. Funder, P.T. Pearce, R. Smith, A.I. Smith, Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242(4878), 583\u2013585 (1988).","journal-title":"Science"},{"issue":"11","key":"2460_CR10","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1681\/asn.2006060570","volume":"17","author":"G Morineau","year":"2006","unstructured":"G. Morineau, V. Sulmont, R. Salomon, B. Fiquet-Kempf, X. Jeunemaitre, J. Nicod, P. Ferrari, Apparent mineralocorticoid excess: report of six new cases and extensive personal experience. J. Am. Soc. Nephrol. 17(11), 3176\u20133184 (2006). https:\/\/doi.org\/10.1681\/asn.2006060570","journal-title":"J. Am. Soc. Nephrol."},{"issue":"52","key":"2460_CR11","doi-asserted-by":"publisher","first-page":"E11248","DOI":"10.1073\/pnas.1716621115","volume":"114","author":"M Yau,","year":"2017","unstructured":"M. Yau,S. Haider, A. Khattab, C. Ling, M. Mat hew, S. Zaidi, M. Bloch, M. Patel, S. Ewert, W. Abdullah, A. Toygar, V. Mudryi, M. Al Badi, M. Alzubdi, R.C. Wilson, H.S. Al Azkawi, H.N. Ozdemir, W. Abu-Amer, J. Hertecant, M. Razzaghy-Azar, J.W. Funder, A. Al Senani, L. Sun, S.M. Kim, T. Yuen, M. Zaidi, M.I. New, Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11beta-hydroxysteroid dehydrogenase type 2 deficiency. Proc. Natl Acad. Sci. USA. 114(52), E11248\u2013E11256 (2017). https:\/\/doi.org\/10.1073\/pnas.1716621115","journal-title":"Proc. Natl Acad. Sci. USA."},{"issue":"2","key":"2460_CR12","doi-asserted-by":"publisher","first-page":"R11","DOI":"10.1016\/0303-7207(94)90176-7","volume":"105","author":"AL Albiston","year":"1994","unstructured":"A.L. Albiston, V.R. Obeyesekere, R.E. Smith, Z.S. Krozowski, Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol. Cell. Endocrinol. 105(2), R11\u2013R17 (1994).","journal-title":"Mol. Cell. Endocrinol."},{"issue":"17","key":"2460_CR13","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1021\/jm900639u","volume":"52","author":"ZK Wan","year":"2009","unstructured":"Z.K. Wan, E. ` Chenail, J. Xiang, H.Q. Li, M. Ipek, J. Bard, K. Svenson, T.S. Mansour, X. Xu, X. Tian, V. Suri, S. Hahm, Y. Xing, C.E. Johnson, X. Li, A. Qadri, D. Panza, M. Perreault, J.F. Tobin, E. Saiah, Efficacious 11beta-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model. J. Med. Chem. 52(17), 5449\u20135461 (2009). https:\/\/doi.org\/10.1021\/jm900639u","journal-title":"J. Med. Chem."},{"issue":"9","key":"2460_CR14","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1021\/ct400314y","volume":"9","author":"R Salomon-Ferrer","year":"2013","unstructured":"R. Salomon-Ferrer, A.W. Gotz, D. Poole, S. Le Grand, R.C. Walker, Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh Ewald. J. Chem. Theory Comput. 9(9), 3878\u20133888 (2013). https:\/\/doi.org\/10.1021\/ct400314y","journal-title":"J. Chem. Theory Comput."},{"issue":"8","key":"2460_CR15","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"J.A. Maier, C. Martinez, K. Kasavajhala, L. Wickstrom, K.E. Hauser, C. Simmerling, ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. J. Chem. Theory Comput. 11(8), 3696\u20133713 (2015). https:\/\/doi.org\/10.1021\/acs.jctc.5b00255","journal-title":"J. Chem. Theory Comput."},{"issue":"5016","key":"2460_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1126\/science.1853201","volume":"253","author":"JU Bowie","year":"1991","unstructured":"J.U. Bowie, R. Luthy, D. Eisenberg, A method to identify protein sequences that fold into a known three-dimensional structure. Science 253(5016), 164\u2013170 (1991). https:\/\/doi.org\/10.1126\/science.1853201","journal-title":"Science"},{"issue":"3","key":"2460_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.tem.2005.02.011","volume":"16","author":"MI New","year":"2005","unstructured":"M.I. New, D.S. Geller, F. Fallo, R.C. Wilson, Monogenic low renin hypertension. Trends Endocrinol. Metab. 16(3), 92\u201397 (2005). https:\/\/doi.org\/10.1016\/j.tem.2005.02.011","journal-title":"Trends Endocrinol. Metab."},{"issue":"3","key":"2460_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1152\/physiolgenomics.00053.2010","volume":"42","author":"JR Manning","year":"2010","unstructured":"J.R. Manning, M.A. Bailey, D.C. Soares, D.R. Dunbar, J.J. Mullins, n silico structure-function analysis of pathological variation in the HSD11B2 gene sequence. Physiol. Genom 42(3), 319\u2013330 (2010). https:\/\/doi.org\/10.1152\/physiolgenomics.00053.2010","journal-title":"Physiol. Genom"},{"issue":"19","key":"2460_CR19","doi-asserted-by":"publisher","first-page":"6056","DOI":"10.1073\/pnas.80.19.6056","volume":"80","author":"ZS Krozowski","year":"1983","unstructured":"Z.S. Krozowski, J.W. Funder, Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc. Natl Acad. Sci. USA. 80(19), 6056\u20136060 (1983). https:\/\/doi.org\/10.1073\/pnas.80.19.6056","journal-title":"Proc. Natl Acad. Sci. USA."},{"issue":"4812","key":"2460_CR20","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1126\/science.3037703","volume":"237","author":"JL Arriza","year":"1987","unstructured":"J.L. Arriza, C. Weinberger, G. Cerelli, T.M. Glaser, B.L. Handelin, D.E. Housman, R.M. Evans, Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237(4812), 268\u2013275 (1987).","journal-title":"Science"},{"issue":"16","key":"2460_CR21","doi-asserted-by":"publisher","first-page":"9202","DOI":"10.1073\/pnas.1633591100","volume":"100","author":"CC Fjeld","year":"2003","unstructured":"C.C. Fjeld, W.T. Birdsong, R.H. Goodman, Differential binding of NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensor. Proc. Natl Acad. Sci. USA. 100(16), 9202\u20139207 (2003). https:\/\/doi.org\/10.1073\/pnas.1633591100","journal-title":"Proc. Natl Acad. Sci. USA."},{"key":"2460_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1161\/01.hyp.0000083340.57063.35","volume":"42","author":"GG Lavery","year":"2003","unstructured":"G.G. Lavery, V. Ronconi, N. Draper, E.H. Rabbitt, V. Lyons, K.E. Chapman, E.A. Walker, C.L. McTernan, G. Giacchetti, F. Mantero, J.R. Seckl, C.R. Edwards, J.M. Connell, M. Hewison, P.M. Stewart, Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension 42, 123\u2013129 (2003). https:\/\/doi.org\/10.1161\/01.hyp.0000083340.57063.35","journal-title":"Hypertension"},{"issue":"3","key":"2460_CR23","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1210\/jcem.86.3.7334","volume":"86","author":"A Odermatt","year":"2001","unstructured":"A. Odermatt, B. Dick, P. Arnold, T. Zaehner, V. Plueschke, M.N. Deregibus, H. Repetto, B.M. Frey, F.J. Frey, P. Ferrari, A mutation in the cofactor-bindingdomain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension. J. Clin. Endocrinol. Metab. 86(3), 1247\u20131252 (2001). https:\/\/doi.org\/10.1210\/jcem.86.3.7334","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11\u201312","key":"2460_CR24","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1515\/jpem-2012-0113","volume":"25","author":"T Al-Harbi","year":"2012","unstructured":"T. Al-Harbi, A. Al-Shaikh, Apparent mineralocorticoid excess syndrome: report of one family with three affected children. J. Pediatr. Endocrinol. Metab. 25(11\u201312), 1083\u20131088 (2012). https:\/\/doi.org\/10.1515\/jpem-2012-0113","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"1","key":"2460_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/nyas.13162","volume":"1376","author":"M Yau","year":"2016","unstructured":"M. Yau, H.S. Azkawi, S. Haider, A. Khattab, M.A. Badi, W. Abdullah, A.A. Senani, R.C. Wilson, T. Yuen, M. Zaidi, M.I. New, A novel mutation in HSD11B2 causes apparent mineralocorticoid excess in an Omani kindred. Ann. N. Y. Acad. Sci. 1376(1), 65\u201371 (2016). https:\/\/doi.org\/10.1111\/nyas.13162","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2460_CR26","doi-asserted-by":"publisher","unstructured":"C.A. Carvajal, A. Tapia-Castillo, A. Vecchiola, R. Baudrand, C.E. Fardella, Classic and nonclassic apparent mineralocorticoid excess syndrome. J. Clin. Endocrinol. Metab. (2019). https:\/\/doi.org\/10.1210\/clinem\/dgz315","DOI":"10.1210\/clinem\/dgz315"},{"issue":"2","key":"2460_CR27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1210\/jc.2018-01197","volume":"104","author":"A Tapia-Castillo","year":"2019","unstructured":"A. Tapia-Castillo, R. Baudrand, A. Vaidya, C. Campino, F. Allende, C. Valdivia, A. Vecchiola, C.F. Lagos, C.A. Fuentes, S. Solari, A. Martinez-Aguayo, H. Garcia, C.A. Carvajal, C.E. Fardella, Clinical, biochemical, and genetic characteristics of \u201cnonclassic\u201d apparent mineralocorticoid excess syndrome. J. Clin. Endocrinol. Metab. 104(2), 595\u2013603 (2019). https:\/\/doi.org\/10.1210\/jc.2018-01197","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"2460_CR28","doi-asserted-by":"publisher","first-page":"E1234","DOI":"10.1210\/jc.2015-1760","volume":"100","author":"F Pizzolo","year":"2015","unstructured":"F. Pizzolo, S. Friso, F. Morandini, F. Antoniazzi, C. Zaltron, S. Udali, A. Gandini, P. Cavarzere, G. Salvagno, A. Giorgetti, G. Speziali, S.W. Choi, O. Olivieri, Apparent mineralocorticoid excess by a novel mutation and epigenetic modulation by HSD11B2 promoter methylation. J. Clin. Endocrinol. Metab. 100(9), E1234\u2013E1241 (2015). https:\/\/doi.org\/10.1210\/jc.2015-1760","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"2460_CR29","doi-asserted-by":"publisher","first-page":"e1610","DOI":"10.1542\/peds.2010-1928","volume":"127","author":"NB Knops","year":"2011","unstructured":"N.B. Knops, L.A. Monnens, J.W. Lenders, E.N. Levtchenko, Apparent mineralocorticoid excess: time of manifestation and complications despite treatment. Pediatrics 127(6), e1610\u2013e1614 (2011). https:\/\/doi.org\/10.1542\/peds.2010-1928","journal-title":"Pediatrics"},{"issue":"4","key":"2460_CR30","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s13312-013-0100-6","volume":"50","author":"Y Parvez","year":"2013","unstructured":"Y. Parvez, O.E. Sayed, Apparent mineralocorticoid excess (AME) syndrome. Indian Pediatr. 50(4), 416\u2013418 (2013).","journal-title":"Indian Pediatr."},{"issue":"4","key":"2460_CR31","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.beem.2015.04.010","volume":"29","author":"MC Zennaro","year":"2015","unstructured":"M.C. Zennaro, S. Boulkroun, F. Fernandes-Rosa, Inherited forms of mineralocorticoid hypertension. Best practice & research. Clin. Endocrinol. Metab. 29(4), 633\u2013645 (2015). https:\/\/doi.org\/10.1016\/j.beem.2015.04.010","journal-title":"Clin. Endocrinol. Metab."},{"issue":"8","key":"2460_CR32","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/jhh.2012.67","volume":"27","author":"K Kosicka","year":"2013","unstructured":"K. Kosicka, M. Cymerys, A. Majc hrzak-Celinska, M. Chuchracki, F.K. Glowka, 11beta-Hydroxysteroid dehydrogenase type 2 in hypertension: comparison of phenotype and genotype analysis. J. Hum. Hypertens 27(8), 510\u2013515 (2013). https:\/\/doi.org\/10.1038\/jhh.2012.67","journal-title":"J. Hum. Hypertens"},{"issue":"1","key":"2460_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4103\/1817-1737.146892","volume":"10","author":"K Zahraldin","year":"2015","unstructured":"K. Zahraldin, I.A. Janahi, T. Ben-Omran, R. Alsulaiman, B. Hamad, A. Imam, Ann. Thorac Med. 10(1), 69\u201372 (2015). https:\/\/doi.org\/10.4103\/1817-1737.146892","journal-title":"Ann. Thorac Med."},{"issue":"3","key":"2460_CR34","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/HJH.0000000000001201","volume":"35","author":"Y Wang","year":"2017","unstructured":"Y. Wang, L. Ma, X. Shu, J. Li, J. Hu, K.P. Law, T. Luo, R. Goswami, S. Yang, S. Zhang, Q. Li, Apparent mineralocorticoid excess caused by a novel mutation in 11beta-hydroxysteroid dehydrogenase type 2 gene. J. Hypertens 35(3), 647\u2013650 (2017). https:\/\/doi.org\/10.1097\/HJH.0000000000001201","journal-title":"J. Hypertens"},{"issue":"Pt A","key":"2460_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jsbmb.2016.02.014","volume":"165","author":"M Razzaghy-Azar","year":"2017","unstructured":"M. Razzaghy-Azar, M. Yau, A. Khattab, M.I. New, Apparent mineralocorticoid excess and the long term treatment of genetic hypertension. J. Steroid Biochem. Mol. Biol. 165(Pt A), 145\u2013150 (2017). https:\/\/doi.org\/10.1016\/j.jsbmb.2016.02.014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"5","key":"2460_CR36","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1590\/S0004-27302004000500015","volume":"48","author":"M Palermo","year":"2004","unstructured":"M. Palermo, M. Quinkler, P.M. Stewart, Apparent mineralocorticoid excess syndrome: an overview. Arquivos Brasileiros de Endocrinologia e Metabologia 48(5), 687\u2013696 (2004). S0004-27302004000500015.","journal-title":"Arquivos Brasileiros de Endocrinologia e Metabologia"},{"issue":"2","key":"2460_CR37","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1677\/joe.1.06019","volume":"186","author":"N Draper","year":"2005","unstructured":"N. Draper, P.M. Stewart, 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J. Endocrinol. 186(2), 251\u2013271 (2005). https:\/\/doi.org\/10.1677\/joe.1.06019","journal-title":"J. Endocrinol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02460-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-020-02460-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02460-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:15:30Z","timestamp":1629418530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-020-02460-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2460"],"URL":"https:\/\/doi.org\/10.1007\/s12020-020-02460-9","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"6 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Fuwai Hospital and carried out in accordance with the principles set out in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all subjects included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}